UNSPSC 51271627: Etidocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C17H28N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6N3B3U8E6, chemically known as 2,6-butyroxylidide, 2-(n-ethylpropylamino)-, hydrochloride, (+-)- but more generally known as etidocaine hydrochloride, which bears US NIH Compound Identifier 37498. European Medicines Agency schedules Etidocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02037MIG.

Most nations, for tariff and trade purposes, schedule etidocaine hydrochloride under HS 29242995 and SITC 51479. As of Q4 2014, ETIDOCAINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Etidocaine hydrochloride bears US NLM identifiers UMLS ID C0733377 and NCI Concept Code C77325. SMILES: CCCN(CC)C(CC)C(=O)NC1C(CCCC1C)C.CL.

UNSPSC 51271627 Etidocaine hydrochloride is a Commodity code covering a single injectable local anesthetic agent. State and local governments procure this pharmaceutical primarily through cooperative purchasing agreements that bundle etidocaine with broader generic pharmaceutical catalogs rather than through direct single-product solicitations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) — a multi-state purchasing vehicle administered by the Minnesota Department of Administration's Office of State Procurement — represents the active issuing structure for this code. State and local health systems, correctional facilities, emergency departments, and surgical centers draw etidocaine through MMCAP's authorized wholesaler network (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) under master pharmaceutical agreements that establish pricing, compliance standards, and supply-chain security requirements.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products, due March 26, 2026, illustrates current procurement activity under this code. The solicitation encompasses participating state and local facilities across Minnesota and Oregon, with contract performance effective July 1, 2026, and a two-year initial term. Manufacturers responding to the RFP must certify cGMP compliance and Drug Supply Chain Security Act (DSCSA) adherence, maintain relationships with at least two of the three authorized wholesalers, and offer pricing through flat-price, net-price, or WAC-minus structures. Evaluation weights price competitiveness at 75 percent, with remaining points distributed across fixed pricing, administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. No set-aside designations or business-classification restrictions appear in the available documentation. Vendors must carry commercial general liability insurance of $5 million per occurrence and professional liability of $2 million, with performance penalties ranging from $200 to $1,500 per violation for reporting delays or supply-chain compliance failures.